Airfinity Launches New Influenza and RSV Intelligence Solution

Posted on Oct 14, 2021

The COVID-19 pandemic has triggered a renewed interest in influenza research and investment. We’re seeing a boom in innovation that is difficult for organisations to stay on top of. Meanwhile, RSV remains one of the last untapped vaccine markets in high-income countries. 

Airfinity’s new Influenza and RSV solution uses real time intelligence and analytics to help decision makers keep up to date with these highly dynamic disease areas, act faster on developments in the space and, ultimately, save more lives from respiratory viruses. 🔬 Inform candidate development and investment 🔬 Track emerging drugs and their efficacy 🔬 Monitor global prevalence rates and disease development 🔬 Understand the relationship between Influenza and COVID-19 Get in touch to book a free session with our analysts where you can all about how the platform can help your organisation.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022